<p class="bodytext">The company had posted a net profit of Rs 171.3 crore for the corresponding period of the previous fiscal, Biocon said in a filing to BSE.</p>.<p class="bodytext">Consolidated revenue from operations of the company stood at Rs 1,057.9 crore for the quarter under consideration as against Rs 1,044.4 crore for the same period year ago.</p>.<p class="bodytext">"This has been a significant quarter for Biocon as we crossed a major milestone of obtaining USFDA approval for biosimilar Trastuzumab partnered with Mylan," Biocon Chairperson and MD Kiran Mazumdar-Shaw said.</p>.<p class="bodytext">Another highlight was the announcement of a new strategic partnership with Sandoz to develop, manufacture and commercialise a portfolio of next wave of biosimilars for global markets, she added.</p>.<p class="bodytext">Small molecules business reported revenue of Rs 369 crore,</p>
<p class="bodytext">The company had posted a net profit of Rs 171.3 crore for the corresponding period of the previous fiscal, Biocon said in a filing to BSE.</p>.<p class="bodytext">Consolidated revenue from operations of the company stood at Rs 1,057.9 crore for the quarter under consideration as against Rs 1,044.4 crore for the same period year ago.</p>.<p class="bodytext">"This has been a significant quarter for Biocon as we crossed a major milestone of obtaining USFDA approval for biosimilar Trastuzumab partnered with Mylan," Biocon Chairperson and MD Kiran Mazumdar-Shaw said.</p>.<p class="bodytext">Another highlight was the announcement of a new strategic partnership with Sandoz to develop, manufacture and commercialise a portfolio of next wave of biosimilars for global markets, she added.</p>.<p class="bodytext">Small molecules business reported revenue of Rs 369 crore,</p>